Cullinan Therapeutics Clears Velinotamig Trial
The clinical trial will evaluate the safety and activity of a novel BCMAxCD3 T cell engager for specific blood disorders.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Should developers prioritize aggressive clinical testing for new treatments for rare, life-threatening autoimmune conditions?
Cullinan Therapeutics has received regulatory clearance in the United States and Australia to begin a Phase 1b/2a clinical trial of its T cell engager, velinotamig. The study will test the drug in adults suffering from immune thrombocytopenia and warm autoimmune hemolytic anemia.
Why it matters
This research targets the pathogenic autoantibodies responsible for cell destruction in these autoimmune conditions by utilizing a BCMAxCD3 T cell engager. The trial aims to address the needs of an estimated 95,300 U.S. adults living with these two blood disorders.
The study, NCT07738822, utilizes a defined course of four subcutaneous doses of velinotamig. This intervention is being evaluated against the baseline of current autoimmune disease management strategies.
The players
Cullinan Therapeutics
A Cambridge-based biotechnology company developing targeted T cell therapies and biologics for autoimmune diseases and oncology.
American College of Rheumatology
A professional medical society representing rheumatologists that hosts an annual convergence for clinical research dissemination.
The details
Velinotamig acts as a BCMAxCD3 T cell engager, a type of protein designed to physically bridge immune T cells to target cells expressing the BCMA protein. By facilitating this connection, the drug intends to trigger an immune response to eliminate the pathogenic autoantibodies that prematurely destroy blood cells in patients with immune thrombocytopenia and warm autoimmune hemolytic anemia. The trial structure includes a Phase 1b multiple-ascending dose segment to determine safety, followed by a Phase 2a dose-expansion phase to assess biological activity.
Timeline
October 27, 2026: Cullinan Therapeutics announces trial clearance.
November 8, 2026: Clinical data presentation scheduled for American College of Rheumatology Convergence.
The Tech Race
This trial represents the expansion of T cell engager technology beyond oncology and into the management of autoimmune disorders. It sits alongside broader industry efforts to repurpose targeted immune-modulating biologics for chronic autoimmune conditions.
This development initiates the research-stage testing process and does not yet affect current treatment options for patients. Future clinical data will determine the potential for this subcutaneous therapy to eventually reach clinical practice.
The takeaway
This trial marks a shift in how T cell engagers are deployed against autoantibody-driven diseases. Stakeholders should track the November 8, 2026, presentation for initial indicators of the safety profile and biological activity.
What happens next
Clinical data regarding velinotamig is scheduled to be presented on November 8, 2026, at the American College of Rheumatology Convergence.
Further reading
For more on the latest developments in therapeutic engineering, visit the Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Should developers prioritize aggressive clinical testing for new treatments for rare, life-threatening autoimmune conditions?
